Information Provided By:
Fly News Breaks for July 18, 2017
NVS, TEVA, MYL
Jul 18, 2017 | 07:59 EDT
Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.
News For MYL;TEVA;NVS From the Last 2 Days
There are no results for your query MYL;TEVA;NVS